Welcome : Guest

BioLineRx Ltd. (Israel) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about BioLineRx Ltd., which is principally a Clinical Development-Stage Biopharmaceutical Company. Illustrated with 72 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-63865
Price: $3500
Company Type: Public
Pages: 77
Date: March 2017
Market Data Tables: 72

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Cancer Drugs......6
Table 1: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......6
Table 2: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......7
Cancer Market......8
Table 3: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others......8
Table 4: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......9
Table 5: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......10
Table 6: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......11
Table 7: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......12
Table 8: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......13
Table 9: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......14
Cancer Patients......15
Table 10: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......15
Table 11: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......16
Table 12: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......17
Table 13: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......18
Table 14: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......19
Table 15: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......20
Table 16: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......21
Table 17: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......22
Table 18: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......23
Table 19: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......24
Table 20: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......25
Hematological Cancer......26
Table 21: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......26
Skin Cancer......27
Table 22: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......27
Multiple Myeloma......28
Table 23: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......28
Table 24: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......29
Non Hodgkin lymphoma (NHL)......30
Table 25: Non Hodgkin lymphoma (NHL) Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Rituxan, Gazyva, and Others......30
Table 26: Non Hodgkin lymphoma (NHL) Market by Category Worldwide (2015) - Percentage Share Breakdown by Volume for Burkitt Lymphoma-Burkitt Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Immunodeficiency-Associated Lymphoproliferative Disorders, Lymphoplasmacytic Lymphoma, Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma, Small Cell Lymphocytic Lymphoma-Chronic Lymphocytic Leukemia, T-Cell and Natural Killer (NK)-Cell Lymphoma, and Others......31
Table 27: Indolent Non Hodgkin lymphoma (NHL) Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Rituxan, Gazyva, and Others......32
Table 28: No. of Non Hodgkin lymphoma (NHL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......33
Table 29: No. of Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......34
Table 30: No. of Indolent Non Hodgkin lymphoma (NHL) (1L) Patients by Category in European Union (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......35
Table 31: No. of Indolent Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in European Union (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......36
Table 32: No. of Non Hodgkin lymphoma (NHL) Patients by Category in the US (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......37
Table 33: No. of Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in the US (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......38
Table 34: No. of Indolent Non Hodgkin lymphoma (NHL) (1L) Patients by Category in the US (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......39
Table 35: No. of Indolent Non Hodgkin lymphoma (NHL) (R/R) Patients by Category in the US (2015) - Percentage Share Breakdown for Rituxan, Gazyva, and Others......40
Immunology......41
Table 36: Immunology Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Dermatology, Gastroenterology, and Rheumatology......41
Diabetes......42
Table 37: Diabetes Market by Region Worldwide (2015) - Percentage Share Breakdown for Africa, Europe, Middle East & North Africa, North America & Caribbean, Southeast Asia, and Western Pacific......42
Table 38: Diabetes Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Insulin Type‐1 Diabetes, Insulin Type‐2 Diabetes, Dipeptidyl Peptidase 4, (DPP4), Glucagon-like Peptide-1 (GLP‐1), Dipeptidyl Peptidase 4, (DPP4) + Biguanide, and Others (includes Sodium-Glucose Co-Transporter-2 (SGLT2), Biguanide, Sulfonylurea, Alpha-Glucosidase Inhibitors, Peroxisome Proliferator-Activated Receptor (PPAR)......43
Table 39: Diabetes Care Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Human Insulins, Modern Insulins, Victoza, and Others......44
Table 40: Type-II Diabetes Treatments Market Worldwide (2015-2020) in US$ Million......45
Table 41: Type II Diabetes Market by Treatment Worldwide (2015) - Percentage Share Breakdown by Value for DPP-IV Inhibitors, GLP-1 Agonists, SGLT-2 Inhibitors and Thiazolidinediones......46
Table 42: Type II Diabetes Market by Insulin Treatment Worldwide (2015) - Percentage Share Breakdown by Value for Diet and Exercise Only, Insulin and Orals and Insulin Only......47
Table 43: Diabetes Healthcare Market by Category in the US (2015) - Percentage Share Breakdown by Value for Anti -Diabetic Agents & Supplies, Doctor Office Visits, Hospital Care, Nursing/Residential Facility Stays, Prescription Medication, and Others......48
Table 44: Diabetes Market by Type in the US (2015) - Percentage Share Breakdown for Insulin Pumps, and Multiple Daily Injections......49
Table 45: Diabetes Market by Type in the US (2015) - Percentage Share Breakdown by Value for Type 1, and Type 2......50
Table 46: No. of Diabetes Patients by Medication in the US (2015) - Percentage Share Breakdown for Insulin and Oral Medication, Insulin Only, No Medication, and Oral Medication Only......51
Diabetes Drugs......52
Table 47: Diabetes Drug Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for DPP-4 Inhibitor, GK Activator, GLP-1 Agonist, GPCR Agonist, IL- Receptor Antagonist, Insulin Analogue, PPAR Agonist, SGLT-2 Inhibitor, and Others......52
Table 48: Diabetes/Metabolic Drugs Market by Category Worldwide (2015) - Percentage Breakdown by Value Sales for DPP-IV Inhibitors, Glitazones, GLP-1 Analogs, Insulins, Sulfonylureas, and Others......53
Table 49: Anti-Diabetic Drug Market by Treatment Class Worldwide (2015) - Percentage Share Breakdown by Value for Diet & Exercise, Incretion, Insulin and Oral Anti-Diabetic......54
Table 50: Antidiabetes Molecules Market by Drug Worldwide (2015) - Percentage Share Breakdown by Value for Metformin, Sulfonylureas, Thiazolidin Ediones and Others......55
Table 51: Anti-Diabetic Drugs Market in China (2015-2020) in RMB Million......56
Table 52: Diabetic Drugs Market by Category in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glinide, Insulin, Sulfonylureas, α-glucosidase Inhibitor, and Others......57
Table 53: Anti-Diabetic Drugs Market by Category in China (2015) - Percentage Share Breakdown by Value for Insulin Drugs and Non-Insulin Drugs......58
Table 54: Diabetes Drugs Market by Product Category in China (2015) - Percentage Share Breakdown by Value for Acarbose, Insulin, Melbine, and Other Diabetes Drugs......59
Table 55: Diabetic Drugs Market by Category in the US (2015) - Percentage Share Breakdown by Value for DPP-IV & SGLT-2, GLP-1, Insulins, and Others......60
Table 56: Diabetic Drugs Market by Non-Insulin Therapy in the US (2015) - Percentage Share Breakdown by Volume for Biguanides, DPP-4 Inhibitor, Human GLP-1 Analogs, SGLT-2 Inhibitor, Sulfonylureas, and Others......61
Table 57: Oral Diabetes Medicine Market in the US (2015) - Percentage Share Breakdown by Value Sales for Dipeptidyl Peptidase-4 (DPP4), Metformin, Sulfonylureas, and Others......62
Non-Insulin Anti-Diabetic Drugs......63
Table 58: Non-Insulin Anti-Diabetic Drugs Market by Product in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glucosidase Inhibitors, Nateglinide, Sulfonylurea and Others......63
Diabetic Macular Edema (DME)......64
Table 59: Diabetic Macular Edema (DME) Market by Drug Treatment Worldwide (2015) - Percentage Share Breakdown by Volume for Avastin, Laser Photocoagulation, Lucentis 0.3 mg, Steroids and Others......64
Table 60: Diabetic Macular Edema (DME) Anti Vascular Endothelial Growth Factor (VEGF) Market by Segment in the US (2015) - Percentage Share Breakdown by Volume for Avastin, Lucentis and Others......65
Cancer Drugs......66
Table 61: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......66
Table 62: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......67
Table 63: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......68
Table 64: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......69
Table 65: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......70
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......71
Table 66: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......71
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......72
Table 67: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......72
Table 68: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Other......73
Immunology/ Immunoglobulin (IG)......74
Table 69: Market Shares of Leading Immunology/ Immunoglobulin Providers in the US (2015) - Percentage Breakdown by Value for Baxter International Inc., CSL Limited, Grifols, S.A., and Others......74
Diabetes Drugs......75
Table 70: Market Shares of Leading Diabetes Care Companies Worldwide (2014) - Percentage Breakdown by Value Sales for Bristol-Myers Squibb (Incl Amylin), Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Sanofi S.A. and Others......75
Table 71: Market Shares of Leading Diabetes Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., and Others......76
Table 72: Market Shares of Leading Anti-Diabetic Drug Manufacturers in India (2014) - Percentage Breakdown by Value for Abbott Healthcare Pvt Ltd., Biocon Limited, Lupin Pharmaceuticals, Inc., MSD Pharmaceuticals Private Limited, Sanofi-Aventis Groupe, Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., and Others......77